Patent application number | Description | Published |
20090155256 | Immunotherapy Regimes Dependent On APOE Status - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 06-18-2009 |
20100221187 | TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment. | 09-02-2010 |
20100266505 | IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 10-21-2010 |
20110229413 | TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment. | 09-22-2011 |
20120070379 | IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 03-22-2012 |
20130084245 | PET MONITORING OF A-BETA-DIRECTED IMMUNOTHERAPY - The present invention provides methods of monitoring Aβ-directed immunotherapy. The methods involve administering a PET ligand that binds to amyloid deposits and detecting the PET ligand in the brain to provide an indication of the level and/or distribution of amyloid deposits. Surprisingly, the data in the present application show that a statistically significant reduction in amyloid deposits occurs early and consistently among patients following initiation of treatment before statistically significant effects of most if not all other markers are detectable. In consequence, the present methods allow early detection of whether a patient is responding to the Aβ-directed immunotherapy and if necessary adjustment of the immunotherapy regime. | 04-04-2013 |
20130209453 | USE OF TAU TO MONITOR IMMUNOTHERAPY - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau. | 08-15-2013 |
20150079074 | Antibody Formulations And Methods - The invention provides antibody formulations and methods useful for prophylaxis or treatment of synucleinopathies, including Parkinson's disease. | 03-19-2015 |